A complete, sustained response of mCRPC to treatment with ABT-888

A newly published report in Frontiers in Oncology is likely to be of considerable interest to many patients currently battling progressive and advanced forms of prostate cancer … but we emphasize that its promise may be limited to a relatively small subset of such patients. … READ MORE …

PARP inhibition, TMPRSS2-EPG gene fusion, and veliparib in mCRPC

A Phase II clinical trial being coordinated by researchers at the University of Michigan Cancer Center is (as far as we know) the first trial ever to explore the potential of treatment for men with metastatic, castration-resistant prostate cancer (mCRPC) who carry the TMPRSS2-EPG fusion gene (as opposed to those who do not). … READ MORE …